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be comparable with published costings for the use of st-
atins to treat hypercholestolemia.
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OBJECTIVE: It is hypothesized that doxazosin’s positive
impact on lipid metabolism, in addition to its antihyper-
tensive effect, will result in a reduced risk of macrovascular
complications in type 2 diabetics, and an improved cost-
effectiveness profile from the NHS perspective when in-
cluded as a part of a combination drug therapy. METH-
ODS: A Markov model was constructed to simulate the
outcomes of patients on drug combinations over the
course of 10 years. Combination therapies examined in
this analysis were: (1) captopril, frusemide, nifedipine;
(2) atenolol, frusemide, nifedipine; and (3) minimal drug
therapy. The effect of substituting doxazosin in place of
any of these drugs was analyzed. Clinical outcomes con-
sidered included stroke, MI, heart failure, angina, PVD,
and death. Transitional probabilities were based on risk
rates presented in UKPDS 38. Risk rates were adjusted
for age and lipid lowering properties of doxazosin using
Framingham risk equations. The Treatment of Mild Hy-
pertension Study was used to quantify the effect of dox-
azosin on lipid levels. Costs of outcomes were calculated
using a Delphi panel to quantify resource consumption
and economic publications to estimate resource values
from the perspective of the NHS. RESULTS: Patients
who incorporated doxazosin into their combination ther-
apy saved 0.36 additional life-years compared to patients
on other combination regimens. This was achieved at in-
cremental costs ranging from £796–£1,741, which re-
sulted in incremental cost-effectiveness ratios of £2,224–
£4,867. When compared to patients on minimal drug
therapy, patients treated with doxazosin saved 0.71 addi-
tional life-years. This was achieved at incremental costs
ranging from £1,124–£2,089, which led to incremental
cost-effectiveness ratios of £1,574–£2,925. CONCLU-
SIONS: In the UK, the inclusion of doxazosin into an an-
tihypertensive combination drug therapy is predicted to
reduce morbidity and mortality due to diabetic mac-
rovascular complications through a marginal investment
in cost.
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Recently, the Heart Outcomes Prevention Evaluation
(HOPE) trial, a randomized double-blind placebo con-
trolled trial in patients at high risk for cardiovascular
events but who did not have left ventricular dysfunction
or heart failure, demonstrated significant survival and
morbidity benefits associated with ramipril use in the
treatment of these patients. OBJECTIVE: To perform an
economic evaluation of ramipril in the treatment of pa-
tients at high risk of cardiovascular events. METHODS:
A decision analytic model was developed based on the re-
sults reported from the HOPE trial. Data from the trial
were combined with NHS cost data to produce estimates
of the potential incremental cost per life-year saved (IC-
PLYS). Both costs and benefits were discounted at 6%
and both discounted and undiscounted results are pre-
sented. Sensitivity analyses were performed to assess the
robustness of the results to key parameter values. RE-
SULTS: Based on a life—expectancy of 5.89 years esti-
mated for those surviving the trial at 5 years, our base
case estimate of cost-effectiveness is £4,406 per life-year
saved (undiscounted) and £5,544 per life-year saved (dis-
counted). The results were most sensitive to assumptions
around life expectancy of those patients who avoided
death through taking ramipril, and insensitive to the up-
per and lower bounds of costs and clinical events.
CONCLUSIONS: The economic analysis reported here
used clinical outcomes from an RCT together with eco-
nomic data from secondary sources in order to compare
the potential costs and effectiveness of using ramipril or
conventional treatment to treat CVD in high-risk pa-
tients. Based on our base case estimate of £6,327 per life-
year saved (discounted), the findings suggest that treating
patients at high risk of CVD events with ramipril is likely
to be a good investment of NHS resources.
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OBJECTIVES: To evaluate the gender-based differences
in the quality of life (QL) and compliance (C) with rou-
tine ambulatory management of essential hypertensives
(EH) living in Belarus, a European country with unique
combination of the important rise in cardiovascular mor-
bidity and mortality, highly restricted financing the state
health care system, and the society experiencing socio-
economic hardships. METHODS: In 234 verified mild to
moderate EH (mean age 47.8  12.2 years, 117 males,
117 females) the QL assessment was performed using the
well-validated, self-administered questionnaires: The Giessen
Somatic Complaints Questionnaire (GSC) and The Gen-
eral Well-Being Adjustment Scale (GWB). At the same
time, C with previously recommended antihypertensive
